28 results on '"Henderson, MA"'
Search Results
2. A survey of surgical management of the sentinel node positive melanoma patient in the post-MSLT2 era
- Author
-
Downs, JS, Subramanian, S, Henderson, MA, Paton, E, Spillane, AJ, Mathy, JA, Gyorki, DE, Downs, JS, Subramanian, S, Henderson, MA, Paton, E, Spillane, AJ, Mathy, JA, and Gyorki, DE
- Abstract
BACKGROUND: The evidence-based management of melanoma patients with a positive sentinel lymph node biopsy (SLNB) has undergone a dramatic shift following publication of practice-changing surgical trials demonstrating no melanoma-specific survival advantage for completion lymph node dissection (CLND) in this scenario. We aimed to survey how surgeons' clinical practice had shifted in response to new evidence from these trials, and at a time when there was starting to become available systemic adjuvant treatments for AJCC Stage III melanoma patients. METHODS: A web-based survey consisting of practice-based questions and hypothetical clinical scenarios about current melanoma practice with regard to positive sentinel node biopsy was developed and sent to the surgical members of a Melanoma and Skin Cancer (MASC) Trials group in December 2018. Responses were analysed using descriptive statistics. RESULTS: There were 212 invitations sent and 65 respondents (31%). Respondents were from 17 countries, 94% of whom practice in specialist melanoma centres or at referral centres. Of these 97% were familiar with the MSLT2 and DeCOG-SLT clinical trials. At survey, 5% of respondents reported routinely recommending CLND and 55% recommend CLND in selected cases. Respondents were most likely to recommend CLND when multiple SLNs were positive. Important factors for surgical decision-making mentioned included size of SLN deposit, number of positive SLNs and likely compliance with the recommended surveillance regimen. CONCLUSION: In line with rapid adoption of published evidence, surgical management of Stage III melanoma has altered significantly, with few surgeons within the cohort now performing routine CLNDs after positive SLNB.
- Published
- 2021
3. Generating CAR T cells from tumor-infiltrating lymphocytes.
- Author
-
Mills, JK, Henderson, MA, Giuffrida, L, Petrone, P, Westwood, JA, Darcy, PK, Neeson, PJ, Kershaw, MH, Gyorki, DE, Mills, JK, Henderson, MA, Giuffrida, L, Petrone, P, Westwood, JA, Darcy, PK, Neeson, PJ, Kershaw, MH, and Gyorki, DE
- Abstract
Background: Tumor-infiltrating lymphocytes (TILs) and chimeric antigen receptor (CAR) T-cell therapies have demonstrated promising, though limited, efficacy against melanoma. Methods: We designed a model system to explore the efficacy of dual specific T cells derived from melanoma patient TILs by transduction with a Her2-specific CAR. Results: Metastatic melanoma cells in our biobank constitutively expressed Her2 antigen. CAR-TIL produced greater amounts of IFN compared with parental TIL, when co-cultured with Her2 expressing tumor lines, including autologous melanoma tumor lines, although no consistent increase in cytotoxicity by TIL was afforded by expression of a CAR. Results of an in vivo study in NSG mice demonstrated tumor shrinkage when CAR-TILs were used in an adoptive cell therapy protocol. Conclusion: Potential limitations of transduced TIL in our study included limited proliferative potential and a terminally differentiated phenotype, which would need addressing in further work before consideration of clinical translation.
- Published
- 2021
4. Radiation-associated breast cancers in a late-effects cohort: Long-term surveillance is essential
- Author
-
Koo, E, Henderson, MA, Dwyer, M, Skandarajah, AR, Koo, E, Henderson, MA, Dwyer, M, and Skandarajah, AR
- Abstract
Aims Survivors of childhood, adolescent, and young adulthood malignancies have an increased risk of subsequent primary malignancies, particularly after exposure to therapeutic radiation. This study aims to evaluate the mode of surveillance and surveillance compliance, incidence and mode of detection of breast cancer, breast cancer phenotype, and outcomes after radiation‐associated breast cancer (RBC) in a late‐effects cohort. Methods Women exposed to therapeutic radiation attending the late effects service from 1st January 2000 to 20th February 2013. All invasive and in‐situ cancers, benign tumors, and deaths were evaluated. The incidence of breast cancer was compared to the Australian general population. Compliance with breast surveillance recommendations, clinicopathological features, and management of breast cancers were examined. Results The prevalence of RBC was 17.1%. Twenty‐eight cases of RBC occurred in 24 women, out of 140 women exposed to chest radiation. Patients whose first attendance was ≥15 years after radiation exposure experienced the highest incidence of RBC at 23%. The incidence of breast cancer was 11.2 times the general population (P < .001). Compliance with surveillance mammography was observed in 18.4%. Breast cancers diagnosed after the first attendance to the service were more likely screen‐detected (P = .002). Most were hormone receptor positive (84.0%), invasive ductal carcinomas (82.1%), and managed with mastectomy (89.3%). Conclusions Patients attending a dedicated late effects service have a high burden of subsequent malignancies generally occurring after long latency. Judicious management with adherence to long‐term surveillance guidelines is advocated.
- Published
- 2020
5. Cutaneous leiomyosarcoma: dermal and subcutaneous
- Author
-
Wong, GN, Webb, A, Gyorki, D, McCormack, C, Tran, P, Ngan, SY, Slavin, J, Henderson, MA, Wong, GN, Webb, A, Gyorki, D, McCormack, C, Tran, P, Ngan, SY, Slavin, J, and Henderson, MA
- Abstract
BACKGROUND AND OBJECTIVES: Leiomyosarcoma of skin (LMS) can be sub-classified on pathology appearances as Dermal or Subcutaneous. The aim of this study was to provide treatment recommendations for these uncommon tumours. METHODS: A retrospective review of all patients with dermal and subcutaneous leiomyosarcoma managed at the Peter MacCallum Cancer Centre, Australia from January 2003 to December 2018 was performed. Eighty-three patients were identified (64 dermal leiomyosarcoma, 19 subcutaneous leiomyosarcoma). RESULTS: Subcutaneous leiomyosarcoma were larger (median size 14 mm dermal, 49 mm subcutaneous, P = 0.01). No patient with a dermal leiomyosarcoma developed metastatic disease compared to 4 of the 19 subcutaneous leiomyosarcoma (5-year overall survivals, 98% and 88%, respectively, P = 0.03). The most common site of metastasis was to the lung. No difference in risk of local recurrence was apparent (5-year recurrence-free survivals were 85% and 78%, respectively, P = 0.17). Adjuvant radiotherapy was used in 16 (25%) dermal leiomyosarcoma patients and 13 (68%) subcutaneous leiomyosarcoma patients (P < 0.001). Local recurrence was uncommon in both tumour subtypes when patients received definitive surgical excision (minimum histological margins of 10 mm as per institutional protocol) regardless of whether radiotherapy was used. The 5-year local recurrence-free survival for dermal leiomyosarcoma treated with radiotherapy was 93% versus 83% without radiotherapy (P = 0.7) and for subcutaneous leiomyosarcoma was 69% and 100%, respectively (P = 0.9). CONCLUSIONS: Dermal leiomyosarcoma have an excellent prognosis, particularly after definitive surgical excision with margins of at least 10 mm. Subcutaneous leiomyosarcoma has poorer outcomes and should be managed by wider excision and considered for adjuvant radiotherapy.
- Published
- 2020
6. Surgical management of recurrent cutaneous squamous cell carcinoma of the head and neck after definitive surgery and radiotherapy
- Author
-
Toppi, J, Tham, YS, Webb, A, Henderson, MA, Rischin, D, Magarey, MJR, Toppi, J, Tham, YS, Webb, A, Henderson, MA, Rischin, D, and Magarey, MJR
- Abstract
BACKGROUND: Surgery is the primary treatment for patients with recurrent head and neck cutaneous squamous cell carcinoma (cSCC) who have previously been treated by definitive surgery and radiotherapy. There are limited published data to direct management and the role of immunotherapy is currently under evaluation. METHODS: This was a retrospective study of patients with at least stage III recurrent head and neck cSCC previously managed by definitive surgery and radiotherapy. RESULTS: A total of 30 patients met the inclusion criteria. Eighty-seven percent were male and the median age at the time of surgery was 79 years. After salvage surgery, 7% developed local recurrence and 43% regional or distant failure. The 2-year overall survival and disease-free survival were 45% (95% confidence interval 24-64) and 11% (95% confidence interval 1-34), respectively. Advanced age was associated with a higher risk of overall mortality (P < 0.05). CONCLUSION: Patients with recurrent head and neck cSCC in the setting of previous radiotherapy have high recurrence rates with poor survival justifying consideration for treatment with anti-PD-1 immunotherapy strategies.
- Published
- 2020
7. IL-15 Preconditioning Augments CAR T Cell Responses to Checkpoint Blockade for Improved Treatment of Solid Tumors
- Author
-
Giuffrida, L, Sek, K, Henderson, MA, House, IG, Lai, J, Chen, AXY, Todd, KL, Petley, E, Mardiana, S, Todorovski, I, Gruber, E, Kelly, MJ, Solomon, BJ, Vervoort, SJ, Johnstone, RW, Parish, IA, Neeson, PJ, Kats, LM, Darcy, PK, Beavis, PA, Giuffrida, L, Sek, K, Henderson, MA, House, IG, Lai, J, Chen, AXY, Todd, KL, Petley, E, Mardiana, S, Todorovski, I, Gruber, E, Kelly, MJ, Solomon, BJ, Vervoort, SJ, Johnstone, RW, Parish, IA, Neeson, PJ, Kats, LM, Darcy, PK, and Beavis, PA
- Abstract
Chimeric antigen receptor (CAR) T cell therapy has been highly successful in hematological malignancies leading to their US Food and Drug Administration (FDA) approval. However, the efficacy of CAR T cells in solid tumors is limited by tumor-induced immunosuppression, leading to the development of combination approaches, such as adjuvant programmed cell death 1 (PD-1) blockade. Current FDA-approved methods for generating CAR T cells utilize either anti-CD3 and interleukin (IL)-2 or anti-CD3/CD28 beads, which can generate a T cell product with an effector/exhausted phenotype. Whereas different cytokine preconditioning milieu, such as IL-7/IL-15, have been shown to promote T cell engraftment, the impact of this approach on CAR T cell responses to adjuvant immune-checkpoint blockade has not been assessed. In the current study, we reveal that the preconditioning of CAR T cells with IL-7/IL-15 increased CAR T cell responses to anti-PD-1 adjuvant therapy. This was associated with the emergence of an intratumoral CD8+CD62L+TCF7+IRF4- population that was highly responsive to anti-PD-1 therapy and mediated the vast majority of transcriptional and epigenetic changes in vivo following PD-1 blockade. Our data indicate that preservation of CAR T cells in a TCF7+ phenotype is crucial for their responsiveness to adjuvant immunotherapy approaches and should be a key consideration when designing clinical protocols.
- Published
- 2020
8. Topical and intralesional therapies for in-transit melanoma
- Author
-
Henderson, MA and Henderson, MA
- Abstract
This report surveys the role of topical and intralesional agents in the management of in-transit melanoma. The extent and progression of in-transit disease is highly variable and many patients can have a protracted period of locoregional control. These agents are useful in the management of patients who have progressed beyond local surgical excision in whom more aggressive therapies, such as isolated limb infusion or use of talimogene laherparepvec, are not appropriate or have failed. In general, these agents are modestly effective and associated with frequent but only minor toxicity. As the mechanism of action of many of these agents includes initiation of a local immune response, combinations with immune checkpoint inhibitors are currently being explored.
- Published
- 2019
9. New treatment paradigms for clinically apparent metastatic melanoma in regional lymph nodes
- Author
-
Henderson, MA, Spillane, J, Hughes, TM, Spillane, AJ, Smithers, BM, Thompson, JF, Henderson, MA, Spillane, J, Hughes, TM, Spillane, AJ, Smithers, BM, and Thompson, JF
- Published
- 2019
10. Accuracy of partial biopsies in the management of cutaneous melanoma
- Author
-
Doolan, BJ, Robinson, AJ, Wolfe, R, Kelly, JW, McLean, C, McCormack, C, Henderson, MA, Pan, Y, Doolan, BJ, Robinson, AJ, Wolfe, R, Kelly, JW, McLean, C, McCormack, C, Henderson, MA, and Pan, Y
- Abstract
BACKGROUND: The recommended method for histopathological diagnosis of cutaneous melanoma is excisional biopsy, although partial biopsies (shave and punch) are often used. Following a partial biopsy, treatment guidelines recommend a narrow excisional biopsy to plan definitive management. There is limited evidence on the benefits of direct wide local excision (WLE) following diagnostic partial biopsies. METHODS: Retrospective cohort study of cutaneous melanoma cases, from two tertiary referral centres from January 2013 to December 2015. Demographic and histopathological data, including tumour thickness (T-stage) from initial biopsy and subsequent excisions, were collected. Logistic regression was used to examine histopathological T-staging between biopsy and subsequent excisions (upstaging). RESULTS: 2304 melanomas (2157 patients) were identified; 455 shave, 308 punch, 14 incisional and 1527 excisional biopsies. Out of 1527, 5 (<1%) excisional biopsies were upstaged from original biopsy T-stage to final WLE; compared to 28/455 (6%) for shave, 45/308 (15%) for punch and 2/14 (14%) for incisional biopsies. Histopathology upstaging were increased with punch (OR, 52.1; 95% CI, 20.5-132.4. P < 0.001) and shave biopsy (OR, 20.0; 95% CI, 7.7-52.0. P < 0.001) compared to excisional biopsy. Upstaging rates of 9.4% for desmoplastic (OR, 6.9; 95% CI, 2.4-19.7. P < 0.001) and 21.9% for acral lentiginous (OR, 18.4; 95% CI, 6.9-49.2. P < 0.001) melanomas were elevated compared to 1.4% for superficial spreading melanoma. CONCLUSIONS: In most cases, partial biopsy (particularly shave biopsy) can provide sufficient information to plan for definitive surgical melanoma management. Punch and incisional biopsies have elevated upstaging rates, a consideration in planning therapy. Partial biopsies of desmoplastic or acral lentiginous melanomas have high rates of upstaging and should have a complete excision prior to definitive treatment.
- Published
- 2019
11. Management of in-transit melanoma metastases: a review
- Author
-
Tie, EN, Henderson, MA, Gyorki, DE, Tie, EN, Henderson, MA, and Gyorki, DE
- Abstract
In-transit metastases (ITM) of cutaneous melanoma are locoregional recurrences confined to the superficial lymphatics that occur in 3.4-6.2% of patients diagnosed with melanoma. ITM are a heterogeneous disease that poses a therapeutic dilemma. Patients may have a prolonged disease trajectory involving multiple or repeat treatment modalities for frequent recurrences. The management of ITM has evolved without the development of a standardized protocol. Owing to the variability of the disease course there are few dedicated clinical trials, with a number of key trials in stage III melanoma excluding ITM patients. Thus, there is a paucity of quality data on the efficacy of the treatment modalities available for ITM and even fewer studies directly comparing modalities. At present the mainstay of ITM treatment is surgical resection, with intralesional therapies, isolated limb infusion and radiotherapy utilized as second-line measures. The developing role of targeted therapies and immunotherapy has yet to be explored completely in these patients. This review addresses the evidence base of the efficacy of the various treatment modalities available and those factors that have impacted their clinical uptake.
- Published
- 2019
12. 'Scalp coordinate system': a new tool to accurately describe cutaneous lesions on the scalp: a pilot study
- Author
-
Alexander, W, Miller, G, Alexander, P, Henderson, MA, Webb, A, Alexander, W, Miller, G, Alexander, P, Henderson, MA, and Webb, A
- Abstract
BACKGROUND: Skin cancers are extremely common and the incidence increases with age. Care for patients with multiple or complicated skin cancers often require multidisciplinary input involving a general practitioner, dermatologist, plastic surgeon and/or radiation oncologist. Timely, efficient care of these patients relies on precise and effective communication between all parties. Until now, descriptions regarding the location of lesions on the scalp have been inaccurate, which can lead to error with the incorrect lesion being excised or biopsied. METHODS: A novel technique for accurately and efficiently describing the location of lesions on the scalp, using a coordinate system, is described (the 'scalp coordinate system' (SCS)). This method was tested in a pilot study by clinicians typically involved in the care of patients with cutaneous malignancies. A mannequin scalp was used in the study. RESULTS: The SCS significantly improved the accuracy in the ability to both describe and locate lesions on the scalp. This improved accuracy comes at a minor time cost. DISCUSSION: The direct and indirect costs arising from poor communication between medical subspecialties (particularly relevant in surgical procedures) are immense. An effective tool used by all involved clinicians is long overdue particularly in patients with scalps with extensive actinic damage, scarring or innocuous biopsy sites. The SCS provides the opportunity to improve outcomes for both the patient and healthcare system.
- Published
- 2019
13. PTPN2 phosphatase deletion in T cells promotes anti-tumour immunity and CAR T-cell efficacy in solid tumours
- Author
-
Wiede, F, Lu, K-H, Du, X, Liang, S, Hochheiser, K, Dodd, GT, Goh, PK, Kearney, C, Meyran, D, Beavis, PA, Henderson, MA, Park, SL, Waithman, J, Zhang, S, Zhang, Z-Y, Oliaro, J, Gebhardt, T, Darcy, PK, Tiganis, T, Wiede, F, Lu, K-H, Du, X, Liang, S, Hochheiser, K, Dodd, GT, Goh, PK, Kearney, C, Meyran, D, Beavis, PA, Henderson, MA, Park, SL, Waithman, J, Zhang, S, Zhang, Z-Y, Oliaro, J, Gebhardt, T, Darcy, PK, and Tiganis, T
- Abstract
Although adoptive T-cell therapy has shown remarkable clinical efficacy in haematological malignancies, its success in combating solid tumours has been limited. Here, we report that PTPN2 deletion in T cells enhances cancer immunosurveillance and the efficacy of adoptively transferred tumour-specific T cells. T-cell-specific PTPN2 deficiency prevented tumours forming in aged mice heterozygous for the tumour suppressor p53. Adoptive transfer of PTPN2-deficient CD8+ T cells markedly repressed tumour formation in mice bearing mammary tumours. Moreover, PTPN2 deletion in T cells expressing a chimeric antigen receptor (CAR) specific for the oncoprotein HER-2 increased the activation of the Src family kinase LCK and cytokine-induced STAT-5 signalling, thereby enhancing both CAR T-cell activation and homing to CXCL9/10-expressing tumours to eradicate HER-2+ mammary tumours in vivo. Our findings define PTPN2 as a target for bolstering T-cell-mediated anti-tumour immunity and CAR T-cell therapy against solid tumours.
- Published
- 2019
14. 1 Versus 2-cm Excision Margins for pT2-pT4 Primary Cutaneous Melanoma (MelMarT): A Feasibility Study
- Author
-
Moncrieff, MD, Gyorki, D, Saw, R, Spillane, AJ, Peach, H, Oudit, D, Geh, J, Dziewulski, P, Wilson, E, Matteucci, P, Pritchard-Jones, R, Bagge, RO, Wright, FC, Crampton, N, Cassell, O, Jallali, N, Berger, A, Kelly, J, Hamilton, S, Durrani, A, Lo, S, Paton, E, Henderson, MA, Moncrieff, MD, Gyorki, D, Saw, R, Spillane, AJ, Peach, H, Oudit, D, Geh, J, Dziewulski, P, Wilson, E, Matteucci, P, Pritchard-Jones, R, Bagge, RO, Wright, FC, Crampton, N, Cassell, O, Jallali, N, Berger, A, Kelly, J, Hamilton, S, Durrani, A, Lo, S, Paton, E, and Henderson, MA
- Abstract
BACKGROUND: There is a lack of consensus regarding optimal surgical excision margins for primary cutaneous melanoma > 1 mm in Breslow thickness (BT). A narrower surgical margin is expected to be associated with lower morbidity, improved quality of life (QoL), and reduced cost. We report the results of a pilot international study (MelMarT) comparing a 1 versus 2-cm surgical margin for patients with primary melanoma > 1 mm in BT. METHODS: This phase III, multicentre trial [NCT02385214] administered by the Australia & New Zealand Medical Trials Group (ANZMTG 03.12) randomised patients with a primary cutaneous melanoma > 1 mm in BT to a 1 versus 2-cm wide excision margin to be performed with sentinel lymph node biopsy. Surgical closure technique was at the discretion of the treating surgeon. Patients' QoL was measured (FACT-M questionnaire) at baseline, 3, 6, and 12 months after randomisation. RESULTS: Between January 2015 and June 2016, 400 patients were randomised from 17 centres in 5 countries. A total of 377 patients were available for analysis. Primary melanomas were located on the trunk (56.9%), extremities (35.6%), and head and neck (7.4%). More patients in the 2-cm margin group required reconstruction (34.9 vs. 13.6%; p < 0.0001). There was an increased wound necrosis rate in the 2-cm arm (0.5 vs. 3.6%; p = 0.036). After 12 months' follow-up, no differences were noted in QoL between groups. DISCUSSION: This pilot study demonstrates the feasibility of a large international RCT to provide a definitive answer to the optimal excision margin for patients with intermediate- to high-risk primary cutaneous melanoma.
- Published
- 2018
15. Restricted venous access after lymph node dissection: no evidence (voodoo)
- Author
-
Snow, H, Riedel, B, Gyorki, D, Henderson, MA, Speakman, D, Snow, H, Riedel, B, Gyorki, D, Henderson, MA, and Speakman, D
- Published
- 2018
16. Importance of preoperative diagnosis for management of patients with suspected retroperitoneal sarcoma
- Author
-
Gyorki, DE, Choong, PFM, Slavin, J, Henderson, MA, Gyorki, DE, Choong, PFM, Slavin, J, and Henderson, MA
- Abstract
Soft tissue sarcoma is an umbrella term which encompasses over 60 histological tumour types. Approximately 15% of soft tissue sarcomas arise in the retroperitoneum. This complex group of tumours poses unique management challenges due to their often large size, histological heterogeneity and complexity of anatomical relationships. This review discusses the management of retroperitoneal tumours including the need for preoperative diagnosis, the evidence for neoadjuvant radiotherapy, the role of multivisceral resection and the importance of a multidisciplinary team approach.
- Published
- 2018
17. Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma
- Author
-
Halse, H, Colebatch, AJ, Petrone, P, Henderson, MA, Mills, JK, Snow, H, Westwood, JA, Sandhu, S, Raleigh, JM, Behren, A, Cebon, J, Darcy, PK, Kershaw, MH, McArthur, GA, Gyorki, DE, Neeson, PJ, Halse, H, Colebatch, AJ, Petrone, P, Henderson, MA, Mills, JK, Snow, H, Westwood, JA, Sandhu, S, Raleigh, JM, Behren, A, Cebon, J, Darcy, PK, Kershaw, MH, McArthur, GA, Gyorki, DE, and Neeson, PJ
- Abstract
A prospective study explored the heterogeneous nature of metastatic melanoma using Multiplex immunohistochemistry (IHC) and flow cytometry (FACS). Multiplex IHC data quantitated immune subset number present intra-tumoral (IT) vs the tumor stroma, plus distance of immune subsets from the tumor margin (TM). In addition, mIHC showed a close association between the presence of IT CD8+ T cells and PDL1 expression in melanoma, which was more prevalent on macrophages than on melanoma cells. In contrast, FACS provided more detailed information regarding the T cell subset differentiation, their activation status and expression of immune checkpoint molecules. Interestingly, mIHC detected significantly higher Treg numbers than FACS and showed preferential CD4+ T cell distribution in the tumor stroma. Based on the mIHC and FACS data, we provide a model which defines metastatic melanoma immune context into four categories using the presence or absence of PDL1+ melanoma cells and/or macrophages, and their location within the tumor or on the periphery, combined with the presence or absence of IT CD8+ T cells. This model interprets melanoma immune context as a spectrum of tumor escape from immune control, and provides a snapshot upon which interpretation of checkpoint blockade inhibitor (CBI) therapy responses can be built.
- Published
- 2018
18. Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy
- Author
-
Beavis, PA, Henderson, MA, Giuffrida, L, Mills, JK, Sek, K, Cross, RS, Davenport, AJ, John, Liza B, Mardiana, S, Slaney, CY, Johnstone, RW, Trapani, JA, Stagg, J, Loi, S, Kats, L, Gyorki, D, Kershaw, MH, Darcy, PK, Beavis, PA, Henderson, MA, Giuffrida, L, Mills, JK, Sek, K, Cross, RS, Davenport, AJ, John, Liza B, Mardiana, S, Slaney, CY, Johnstone, RW, Trapani, JA, Stagg, J, Loi, S, Kats, L, Gyorki, D, Kershaw, MH, and Darcy, PK
- Published
- 2017
19. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
- Author
-
Burr, ML, Sparbier, CE, Chan, Y-C, Williamson, JC, Woods, K, Beavis, PA, Lam, EYN, Henderson, MA, Bell, CC, Stolzenburg, S, Gilan, O, Bloor, S, Noori, T, Morgens, DW, Bassik, MC, Neeson, PJ, Behren, A, Darcy, PK, Dawson, S-J, Voskoboinik, I, Trapani, JA, Cebon, J, Lehner, PJ, Dawson, MA, Burr, ML, Sparbier, CE, Chan, Y-C, Williamson, JC, Woods, K, Beavis, PA, Lam, EYN, Henderson, MA, Bell, CC, Stolzenburg, S, Gilan, O, Bloor, S, Noori, T, Morgens, DW, Bassik, MC, Neeson, PJ, Behren, A, Darcy, PK, Dawson, S-J, Voskoboinik, I, Trapani, JA, Cebon, J, Lehner, PJ, and Dawson, MA
- Abstract
Cancer cells exploit the expression of the programmed death-1 (PD-1) ligand 1 (PD-L1) to subvert T-cell-mediated immunosurveillance. The success of therapies that disrupt PD-L1-mediated tumour tolerance has highlighted the need to understand the molecular regulation of PD-L1 expression. Here we identify the uncharacterized protein CMTM6 as a critical regulator of PD-L1 in a broad range of cancer cells, by using a genome-wide CRISPR-Cas9 screen. CMTM6 is a ubiquitously expressed protein that binds PD-L1 and maintains its cell surface expression. CMTM6 is not required for PD-L1 maturation but co-localizes with PD-L1 at the plasma membrane and in recycling endosomes, where it prevents PD-L1 from being targeted for lysosome-mediated degradation. Using a quantitative approach to profile the entire plasma membrane proteome, we find that CMTM6 displays specificity for PD-L1. Notably, CMTM6 depletion decreases PD-L1 without compromising cell surface expression of MHC class I. CMTM6 depletion, via the reduction of PD-L1, significantly alleviates the suppression of tumour-specific T cell activity in vitro and in vivo. These findings provide insights into the biology of PD-L1 regulation, identify a previously unrecognized master regulator of this critical immune checkpoint and highlight a potential therapeutic target to overcome immune evasion by tumour cells.
- Published
- 2017
20. Human glandular organoid formation in murine engineering chambers after collagenase digestion and flow cytometry isolation of normal human breast tissue single cells
- Author
-
Huo, CW, Huang, D, Chew, GL, Hill, P, Vohora, A, Ingman, WV, Glynn, DJ, Godde, N, Henderson, MA, Thompson, EW, Britt, KL, Huo, CW, Huang, D, Chew, GL, Hill, P, Vohora, A, Ingman, WV, Glynn, DJ, Godde, N, Henderson, MA, Thompson, EW, and Britt, KL
- Abstract
Women with high mammographic density (MD) are at increased risk of breast cancer (BC) after adjustment for age and body mass index. We have developed a murine biochamber model in which both high MD (HMD) and low MD (LMD) tissue can be propagated. Here, we tested whether cells isolated by collagenase digestion and fluorescence-activated cell sorting (FACS) from normal breast can be reconstituted in our biochamber model, which would allow cell-specific manipulations to be tested. Fresh breast tissue was collected from women (n = 7) undergoing prophylactic mastectomy. The tissue underwent collagenase digestion overnight and, in some cases, additional FACS enrichment to obtain mature epithelial, luminal progenitor, mammary stem, and stromal cells. Cells were then transferred bilaterally into biochambers in SCID mice (n = 5-7) and incubated for 6 weeks, before harvesting for histological analyses, and immunohistochemical staining for cytokeratins (CK), vimentin, Ki-67, murine macrophages, and Cleaved Caspase-3. Biochambers inoculated with single cells after collagenase digestion or with flow cytometry contained glandular structures of human origin (human vimentin-positive), which expressed CK-14 and pan-CK, and were proliferating (Ki-67-positive). Glandular structures from the digested tissues were smaller than those in chambers seeded with finely chopped intact mammary tissue. Mouse macrophage infiltration was higher in the chambers arising from digested tissues. Pooled single cells and FACS fractionated cells were viable in the murine biochambers and formed proliferating glandular organoids of human origin. This is among the first report to demonstrate the success of formed human glandular organoids from isolated primary mammary cells in the murine biochamber model.
- Published
- 2016
21. Intralesional PV-10 for in-transit melanomaA single-center experience
- Author
-
Lippey, J, Bousounis, R, Behrenbruch, C, McKay, B, Spillane, J, Henderson, MA, Speakman, D, Gyorki, DE, Lippey, J, Bousounis, R, Behrenbruch, C, McKay, B, Spillane, J, Henderson, MA, Speakman, D, and Gyorki, DE
- Published
- 2016
22. Excision margins and sentinel lymph node status as prognostic factors in thick melanoma of the head and neck: A retrospective analysis
- Author
-
Ruskin, O, Sanelli, A, Herschtal, A, Webb, A, Dixon, B, Pohl, M, Donahoe, S, Spillane, J, Henderson, MA, Gyorki, DE, Ruskin, O, Sanelli, A, Herschtal, A, Webb, A, Dixon, B, Pohl, M, Donahoe, S, Spillane, J, Henderson, MA, and Gyorki, DE
- Published
- 2016
23. High mammographic density is associated with an increase in stromal collagen and immune cells within the mammary epithelium
- Author
-
Huo, CW, Chew, G, Hill, P, Huang, D, Ingman, W, Hodson, L, Brown, KA, Magenau, A, Allam, AH, McGhee, E, Timpson, P, Henderson, MA, Thompson, EW, Britt, K, Huo, CW, Chew, G, Hill, P, Huang, D, Ingman, W, Hodson, L, Brown, KA, Magenau, A, Allam, AH, McGhee, E, Timpson, P, Henderson, MA, Thompson, EW, and Britt, K
- Abstract
INTRODUCTION: Mammographic density (MD), after adjustment for a women's age and body mass index, is a strong and independent risk factor for breast cancer (BC). Although the BC risk attributable to increased MD is significant in healthy women, the biological basis of high mammographic density (HMD) causation and how it raises BC risk remain elusive. We assessed the histological and immunohistochemical differences between matched HMD and low mammographic density (LMD) breast tissues from healthy women to define which cell features may mediate the increased MD and MD-associated BC risk. METHODS: Tissues were obtained between 2008 and 2013 from 41 women undergoing prophylactic mastectomy because of their high BC risk profile. Tissue slices resected from the mastectomy specimens were X-rayed, then HMD and LMD regions were dissected based on radiological appearance. The histological composition, aromatase immunoreactivity, hormone receptor status and proliferation status were assessed, as were collagen amount and orientation, epithelial subsets and immune cell status. RESULTS: HMD tissue had a significantly greater proportion of stroma, collagen and epithelium, as well as less fat, than LMD tissue did. Second harmonic generation imaging demonstrated more organised stromal collagen in HMD tissues than in LMD tissues. There was significantly more aromatase immunoreactivity in both the stromal and glandular regions of HMD tissues than in those regions of LMD tissues, although no significant differences in levels of oestrogen receptor, progesterone receptor or Ki-67 expression were detected. The number of macrophages within the epithelium or stroma did not change; however, HMD stroma exhibited less CD206(+) alternatively activated macrophages. Epithelial cell maturation was not altered in HMD samples, and no evidence of epithelial-mesenchymal transition was seen; however, there was a significant increase in vimentin(+)/CD45(+) immune cells within the epithelial layer in HMD
- Published
- 2015
24. Mammographic density-a review on the current understanding of its association with breast cancer
- Author
-
Huo, CW, Chew, GL, Britt, KL, Ingman, WV, Henderson, MA, Hopper, JL, Thompson, EW, Huo, CW, Chew, GL, Britt, KL, Ingman, WV, Henderson, MA, Hopper, JL, and Thompson, EW
- Abstract
There has been considerable recent interest in the genetic, biological and epidemiological basis of mammographic density (MD), and the search for causative links between MD and breast cancer (BC) risk. This report will critically review the current literature on MD and summarize the current evidence for its association with BC. Keywords 'mammographic dens*', 'dense mammary tissue' or 'percent dens*' were used to search the existing literature in English on PubMed and Medline. All reports were critically analyzed. The data were assigned to one of the following aspects of MD: general association with BC, its relationship with the breast hormonal milieu, the cellular basis of MD, the generic variations of MD, and its significance in the clinical setting. MD adjusted for age, and BMI is associated with increased risk of BC diagnosis, advanced tumour stage at diagnosis and increased risk of both local recurrence and second primary cancers. The MD measures that predict BC risk have high heritability, and to date several genetic markers associated with BC risk have been found to also be associated with these MD risk predictors. Change in MD could be a predictor of the extent of chemoprevention with tamoxifen. Although the biological and genetic pathways that determine and perhaps modulate MD remain largely unresolved, significant inroads are being made into the understanding of MD, which may lead to benefits in clinical screening, assessment and treatment strategies. This review provides a timely update on the current understanding of MD's association with BC risk.
- Published
- 2014
25. Effects of Tamoxifen and oestrogen on histology and radiographic density in high and low mammographic density human breast tissues maintained in murine tissue engineering chambers
- Author
-
Chew, GL, Huo, CW, Huang, D, Blick, T, Hill, P, Cawson, J, Frazer, H, Southey, MC, Hopper, JL, Britt, K, Henderson, MA, Haviv, I, Thompson, EW, Chew, GL, Huo, CW, Huang, D, Blick, T, Hill, P, Cawson, J, Frazer, H, Southey, MC, Hopper, JL, Britt, K, Henderson, MA, Haviv, I, and Thompson, EW
- Abstract
Mammographic density (MD) is a strong risk factor for breast cancer. It is altered by exogenous endocrine treatments, including hormone replacement therapy and Tamoxifen. Such agents also modify breast cancer (BC) risk. However, the biomolecular basis of how systemic endocrine therapy modifies MD and MD-associated BC risk is poorly understood. This study aims to determine whether our xenograft biochamber model can be used to study the effectiveness of therapies aimed at modulating MD, by examine the effects of Tamoxifen and oestrogen on histologic and radiographic changes in high and low MD tissues maintained within the biochamber model. High and low MD human tissues were precisely sampled under radiographic guidance from prophylactic mastectomy fresh specimens of high-risk women, then inserted into separate vascularized murine biochambers. The murine hosts were concurrently implanted with Tamoxifen, oestrogen or placebo pellets, and the high and low MD biochamber tissues maintained in the murine host environment for 3 months, before the high and low MD biochamber tissues were harvested for histologic and radiographic analyses. The radiographic density of high MD tissue maintained in murine biochambers was decreased in Tamoxifen-treated mice compared to oestrogen-treated mice (p = 0.02). Tamoxifen treatment of high MD tissue in SCID mice led to a decrease in stromal (p = 0.009), and an increase in adipose (p = 0.023) percent areas, compared to placebo-treated mice. No histologic or radiographic differences were observed in low MD biochamber tissue with any treatment. High MD biochamber tissues maintained in mice implanted with Tamoxifen, oestrogen or placebo pellets had dynamic and measurable histologic compositional and radiographic changes. This further validates the dynamic nature of the MD xenograft model, and suggests the biochamber model may be useful for assessing the underlying molecular pathways of Tamoxifen-reduced MD, and in testing of other pharmacologic
- Published
- 2014
26. Dynamic changes in high and low mammographic density human breast tissues maintained in murine tissue engineering chambers during various murine peripartum states and over time
- Author
-
Chew, GL, Huang, D, Huo, CW, Blick, T, Hill, P, Cawson, J, Frazer, H, Southey, MD, Hopper, JL, Henderson, MA, Haviv, I, Thompson, EW, Chew, GL, Huang, D, Huo, CW, Blick, T, Hill, P, Cawson, J, Frazer, H, Southey, MD, Hopper, JL, Henderson, MA, Haviv, I, and Thompson, EW
- Abstract
Mammographic density (MD) is a strong heritable risk factor for breast cancer, and may decrease with increasing parity. However, the biomolecular basis for MD-associated breast cancer remains unclear, and systemic hormonal effects on MD-associated risk is poorly understood. This study assessed the effect of murine peripartum states on high and low MD tissue maintained in a xenograft model of human MD. Method High and low MD human breast tissues were precisely sampled under radiographic guidance from prophylactic mastectomy specimens of women. The high and low MD tissues were maintained in separate vascularised biochambers in nulliparous or pregnant SCID mice for 4 weeks, or mice undergoing postpartum involution or lactation for three additional weeks. High and low MD biochamber material was harvested for histologic and radiographic comparisons during various murine peripartum states. High and low MD biochamber tissues in nulliparous mice were harvested at different timepoints for histologic and radiographic comparisons. Results High MD biochamber tissues had decreased stromal (p = 0.0027), increased adipose (p = 0.0003) and a trend to increased glandular tissue areas (p = 0.076) after murine postpartum involution. Stromal areas decreased (p = 0.042), while glandular (p = 0.001) and adipose areas (p = 0.009) increased in high MD biochamber tissues during lactation. A difference in radiographic density was observed in high (p = 0.0021) or low MD biochamber tissues (p = 0.004) between nulliparous, pregnant and involution groups. No differences in tissue composition were observed in high or low MD biochamber tissues maintained for different durations, although radiographic density increased over time. Conclusion High MD biochamber tissues had measurable histologic changes after postpartum involution or lactation. Alterations in radiographic density occurred in biochamber tissues between different peripartum states and over time. These findings demonstrate the dynamic na
- Published
- 2013
27. High and low mammographic density human breast tissues maintain histological differential in murine tissue engineering chambers
- Author
-
Chew, GL, Huang, D, Lin, SJ, Huo, C, Blick, T, Henderson, MA, Hill, P, Cawson, J, Morrison, WA, Campbell, IG, Hopper, JL, Southey, MC, Haviv, I, Thompson, EW, Chew, GL, Huang, D, Lin, SJ, Huo, C, Blick, T, Henderson, MA, Hill, P, Cawson, J, Morrison, WA, Campbell, IG, Hopper, JL, Southey, MC, Haviv, I, and Thompson, EW
- Abstract
Mammographic density (MD) is the area of breast tissue that appears radiologically white on mammography. Although high MD is a strong risk factor for breast cancer, independent of BRCA1/2 mutation status, the molecular basis of high MD and its associated breast cancer risk is poorly understood. MD studies will benefit from an animal model, where hormonal, gene and drug perturbations on MD can be measured in a preclinical context. High and low MD tissues were selectively sampled by stereotactic biopsy from operative specimens of high-risk women undergoing prophylactic mastectomy. The high and low MD tissues were transferred into separate vascularised biochambers in the groins of SCID mice. Chamber material was harvested after 6 weeks for histological analyses and immunohistochemistry for cytokeratins, vimentin and a human-specific mitochondrial antigen. Within-individual analysis was performed in replicate mice, eliminating confounding by age, body mass index and process-related factors, and comparisons were made to the parental human tissue. Maintenance of differential MD post-propagation was assessed radiographically. Immunohistochemical staining confirmed the preservation of human glandular and stromal components in the murine biochambers, with maintenance of radiographic MD differential. Propagated high MD regions had higher stromal (p = 0.0002) and lower adipose (p = 0.0006) composition, reflecting the findings in the original human breast tissue, although glands appeared small and non-complex in both high and low MD groups. No significant differences were observed in glandular area (p = 0.4) or count (p = 0.4) between high and low MD biochamber tissues. Human mammary glandular and stromal tissues were viably maintained in murine biochambers, with preservation of differential radiographic density and histological features. Our study provides a murine model for future studies into the biomolecular basis of MD as a risk factor for breast cancer.
- Published
- 2012
28. Identification of circulating tumour cells in early stage breast cancer patients using multi marker immunobead RT-PCR
- Author
-
Raynor, MP, Stephenson, S-A, Pittman, KB, Walsh, DCA, Henderson, MA, Dobrovic, A, Raynor, MP, Stephenson, S-A, Pittman, KB, Walsh, DCA, Henderson, MA, and Dobrovic, A
- Abstract
INTRODUCTION: The ability to screen blood of early stage operable breast cancer patients for circulating tumour cells is of potential importance for identifying patients at risk of developing distant relapse. We present the results of a study of the efficacy of the immunobead RT-PCR method in identifying patients with circulating tumour cells. RESULTS: Immunomagnetic enrichment of circulating tumour cells followed by RT-PCR (immunobead RT-PCR) with a panel of five epithelial specific markers (ELF3, EPHB4, EGFR, MGB1 and TACSTD1) was used to screen for circulating tumour cells in the peripheral blood of 56 breast cancer patients. Twenty patients were positive for two or more RT-PCR markers, including seven patients who were node negative by conventional techniques. Significant increases in the frequency of marker positivity was seen in lymph node positive patients, in patients with high grade tumours and in patients with lymphovascular invasion. A strong trend towards improved disease free survival was seen for marker negative patients although it did not reach significance (p = 0.08). CONCLUSION: Multi-marker immunobead RT-PCR analysis of peripheral blood is a robust assay that is capable of detecting circulating tumour cells in early stage breast cancer patients.
- Published
- 2009
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.